Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience
- 21 July 2022
- journal article
- research article
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 4 (1) , 1-6
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinibJournal of Human Genetics, 2015
- Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylateIndian Journal of Medical and Paediatric Oncology, 2014
- The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinibLeukemia, 2013
- Molecular and cellular bases of chronic myeloid leukemiaProtein & Cell, 2010
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO studyBlood, 2009
- Molecular biology of bcr-abl1–positive chronic myeloid leukemiaBlood, 2009
- Correlation of BCR/ABL transcript variants with patients’ characteristics in childhood chronic myeloid leukaemiaEuropean Journal of Haematology, 2009
- Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based studyThe Lancet Oncology, 2006
- BCR/ABLp210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML)Clinical and Laboratory Haematology, 2002
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002